Brief: Palisade Bio Completes Dosing In Phase 1A Portion Of Ongoing Phase 1A/B Study Of Pali-2108
09/04/2025 13:35
April 9 (Reuters) - Palisade Bio Inc PALI.O: PALISADE BIO COMPLETES DOSING IN PHASE 1A PORTION OF ONGOING PHASE 1A/B STUDY OF PALI-2108 PALISADE BIO INC - TO REPORT TOPLINE DATA FROM PHASE 1A STUDY BY END OF MAY 2025 Source text: ID:nGNX8zpYRP Further company coverage: PALI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palisade Bio
See all newsPalisade Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Palisade Bio Q2 net loss widens on higher R&D costs
Brief: Palisade Bio Q2 EPS USD -0.05
Palisade Bio Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Palisade Bio Inc - May Offer And Sell Up To $300 Million Of Securities - SEC Filing